NEW YORK, September 20 — New to The Street, the sponsored and syndicated business television program founded in 2009, aired an episode Saturday night featuring executive interviews with four companies, among them BioVie Inc. (Nasdaq:BIVI), whose president and CEO used the broadcast to discuss recently announced Phase 2 ADDRESS-LC results. The episode ran Saturday, September 19, 2026, at 6:30 PM Eastern Time across Bloomberg Television’s United States, Latin America, and Middle East and North Africa markets.
The announcement was issued as a press release dated September 19, 2026 at 11:45 EDT from New York.
BioVie’s Long COVID Data
BioVie president and CEO Cuong Do discussed the company’s recently announced Phase 2 ADDRESS-LC results evaluating bezisterim in patients suffering from Long COVID. According to the announcement, Do explained encouraging signals observed across multiple clinical endpoints, including areas related to fatigue, post-exertional malaise, and cognitive symptoms. He also discussed what the results could mean for continued clinical development of bezisterim, the design of a potential Phase 3 program, and the millions of patients still searching for an effective Long COVID treatment.
BioVie is described as a clinical-stage biopharmaceutical company developing therapies targeting neurological, neurodegenerative, and advanced liver diseases. Bezisterim is designed to address inflammation and insulin resistance, biological processes believed to contribute to Long COVID and several neurodegenerative conditions.
Antibiotics, AI and Public Safety
Acurx Pharmaceuticals CEO David Luci presented the company’s work developing a new class of antibiotics for difficult-to-treat bacterial infections. Its lead product candidate, ibezapolstat, is being developed as a potential treatment for Clostridioides difficile infection, commonly known as C. difficile or C. diff. The interview explored recent scientific developments, the company’s global intellectual-property portfolio, and plans for advancing ibezapolstat toward Phase 3 clinical development.
Lantern Pharma CEO Panna Sharma discussed how the company applies artificial intelligence, machine learning, and biomarker-driven drug development to transform the economics and timeline of oncology research. Lantern’s proprietary RADR artificial-intelligence platform is designed to help identify patient populations, uncover new therapeutic indications, and accelerate development of precision oncology drug candidates.
SafeSpace Global CEO Scott Boruff presented an artificial intelligence-powered security platform designed to improve threat detection, emergency response, and situational awareness across schools, senior-care facilities, and other vulnerable environments. The interview explored how the company combines advanced technology with real-world security applications to help organizations identify risks earlier, coordinate responses faster, and create safer spaces for the communities they serve.
What to Watch
Vince Caruso, co-founder and CEO of New to The Street, said: “Tonight’s broadcast brings together four companies addressing major global challenges—from Long COVID and antibiotic resistance to cancer treatment and public safety.
Our international television distribution and rapidly growing digital ecosystem give innovative companies a powerful platform to communicate directly with investors, industry leaders and the public.” The program is distributed weekly across the United States, Latin America, the Middle East and North Africa, and Southeast Asia, and the company says its media ecosystem includes more than 6.3 million YouTube subscribers across New to The Street TV and NewsOut, plus social-media amplification, earned-media distribution, and billboard exposure in New York City’s Times Square.
The announcement notes that certain statements made during sponsored interviews may constitute forward-looking statements involving risks and uncertainties, that viewers should review each featured company’s public filings and official disclosures, and that New to The Street does not provide investment advice and its programming should not be considered a recommendation to purchase or sell any security. For corporate interviews and 2026-2027 media opportunities, the contact listed is John at [email protected]. Consult your doctor for medical advice.
Sources
- BioVie CEO shares insights into long COVID trial – ICYMI
- Bezisterim may help with some Long COVID… – The Sick Times
